Oct 30, 2026, 10:06 UTC
Sumitomo Pharma announced that an iPS-cell-derived Parkinson’s disease treatment, Amchepri, was transplanted into a patient for the first time in clinical practice after its conditional and time-limited approval.
Source:Oct 30, 2026, 08:35 UTC
Sumitomo Pharma forecast revenue for the fiscal year ending March 2027 to rise 25% to ¥565 billion and operating profit to fall 3% to ¥104 billion, raising both forecasts.
Source:Oct 30, 2026, 06:30 UTC
Sumitomo Pharma revised its full-year net profit forecast for the fiscal year ending March 2027 upward by 22.1% to ¥94.0 billion.
Oct 30, 2026, 06:30 UTC
Sumitomo Pharma reported consolidated net profit of ¥38.2 billion for the six months ended September 2026, down 61.3% year over year.
Source:Oct 30, 2026, 06:30 UTC
Sumitomo Pharma announced a ¥15 year-end dividend for the fiscal year ending March 2027, resuming dividends after four fiscal years.
Oct 27, 2026, 02:31 UTC
Sumitomo Pharma shares rose sharply after enzomenib received U.S. FDA Breakthrough Therapy designation.
Source:Oct 27, 2026, 02:30 UTC
Japanese-listed stocks were ranked by gains from the October 27 opening price to 11:30 a.m., led by Schoo at 23.4%.
Source:Oct 27, 2026, 01:55 UTC
The U.S. Food and Drug Administration designated Sumitomo Pharma’s investigational cancer drug enzomenib as a Breakthrough Therapy.
Oct 24, 2026, 23:15 UTC
Tokyo Stock Exchange Prime Market margin short positions increased from October 9 to October 16, 2026, with Kobe Bussan leading the listed increases at 3.482 million shares.
Source:Oct 24, 2026, 23:00 UTC
The Tokyo Stock Exchange's credit-trading data ranked 50 Prime Market stocks by the weekly decrease in margin-buying balances from October 9 to October 16, with Tokio Marine Holdings leading at a decline of 9.165 million shares.
Source:Oct 16, 2026, 23:50 UTC
Japanese stocks highlighted in the October 13–16 roundup rose sharply, including Cluster, Showcase, SecureVe, MonotaRO, Sumitomo Pharma and numerous other listed companies.
Source:Oct 15, 2026, 22:15 UTC
Sumitomo Pharma shares closed at 1,842 yen, up 251.5 yen.
Source:Oct 15, 2026, 02:19 UTC
Sumitomo Pharma shares rebounded sharply.
Source:Oct 15, 2026, 00:03 UTC
Japanese equities showed broad special-quote selling, with 182 stocks under special sell quotes versus 23 under special buy quotes; Kioxia led sell orders at ¥40.2 billion against ¥24.9 billion in buy orders, while Tobu Juhan led buy orders at ¥7.72 billion against no sell orders.
Source:Oct 2, 2026, 20:00 UTC
A research group including Nagoya University and LACERA, a joint venture of Sumitomo Chemical and Sumitomo Pharma, announced that pituitary tissue derived from human embryonic stem cells restored function when transplanted into monkeys, a step toward treating hypopituitarism.
Source: